Arena To Advance GI, Derm Ambitions With $800m From United For PAH Candidate
With $800m in upfront cash from United Therapeutics and $400m pegged to approvals for ralinepag, Arena gets capital for its R&D ambitions and a partner of choice to advance its Phase III PAH compound.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.
Arena announced encouraging data from a small Phase IIa study for olorinab (APD371) in abdominal pain associated with Crohn's disease as the company continues a streak of good news after two of its more advanced clinical-stage programs posted positive results.